{"id":5611,"date":"2022-11-07T07:00:00","date_gmt":"2022-11-07T06:00:00","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-therapeutics-presenterar-pa-stora-aktiedagen-i-goteborg\/"},"modified":"2022-11-07T07:00:00","modified_gmt":"2022-11-07T06:00:00","slug":"stayble-therapeutics-presenterar-pa-stora-aktiedagen-i-goteborg","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-therapeutics-presenterar-pa-stora-aktiedagen-i-goteborg\/","title":{"rendered":"Stayble Therapeutics presenterar p\u00e5 Stora Aktiedagen i G\u00f6teborg"},"content":{"rendered":"<p style=\"margin-bottom:0pt;margin-top:12px\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Tisdag den 8 november kl 11.00-11.30 medverkar Stayble Therapeutics p\u00e5 Aktiespararnas evenemang. Andreas Gerward presenterar Bolaget och svara p\u00e5 fr\u00e5gor. Ta del av presentationen live p\u00e5 webben, via www.aktiespararna.se\/tv\/live. Evenemanget \u00e4r \u00f6ppet f\u00f6r alla och kr\u00e4ver inget medlemskap hos Aktiespararna. Ingen anm\u00e4lan kr\u00e4vs f\u00f6r att f\u00f6lja evenemanget digitalt.<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Passa p\u00e5 och st\u00e4ll dina fr\u00e5gor till Andreas genom att skicka ett sms till 079-347 98 45 eller maila till event@aktiespararna.se. Fr\u00e5gorna kommer att f\u00f6rmedlas av Aktiespararnas moderator i samband med fr\u00e5gestunden efter presentationen. Du kan skicka in dina fr\u00e5gor redan nu eller i samband med presentationen.<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\"><strong>Information<\/strong><\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">N\u00e4r: 8 november kl 11.00-11.30<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Lives\u00e4nding: https:\/\/www.youtube.com\/watch?v=GSd-1uBkUf0 <\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Den inspelade presentationen kommer att i efterhand publiceras p\u00e5 Staybles hemsida. <\/span><\/p>\n<p style=\"font-family:arial,helvetica,sans-serif;margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt;height:0pt;text-align:left\"><img alt=\"\" height=\"377\" src=\"https:\/\/mb.cision.com\/Public\/18889\/3662079\/927dba149067ae1a_800x800ar.png\" style=\"margin-left:-0.1pt;margin-top:2.25pt\" width=\"669\"><\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"font-family:arial,helvetica,sans-serif;font-size:9pt;margin-bottom:10pt;margin-top:0pt;text-align:left\">\n<h2 style=\"font-size:14pt;margin-bottom:6pt;margin-top:0pt;text-align:left\"><span style=\"color:#305584;font-family:arial,helvetica,sans-serif;font-size:9pt;font-weight:normal\">F\u00f6r mer information<\/span><\/h2>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Andreas Gerward, VD Stayble Therapeutics AB<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">E-post: andreas.gerward@stayble.se <\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Telefon: +46 730 808<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">397<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<h2 style=\"font-size:14pt;margin-bottom:6pt;margin-top:0pt;text-align:left\"><span style=\"color:#305584;font-family:arial,helvetica,sans-serif;font-size:9pt;font-weight:normal\">Om Stayble Therapeutics AB<\/span><\/h2>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Stayble \u00e4r ett kliniskt l\u00e4kemedelsbolag som utvecklar injektionsbehandlingen STA363 mot kronisk diskrelaterad ryggsm\u00e4rta. Behandlingen riktar sig till patienter som inte blir hj\u00e4lpta av sjukgymnastik och sm\u00e4rtstillande preparat. Injektionen ges vid ett tillf\u00e4lle och effekten ber\u00e4knas kvarst\u00e5 hela livet och kr\u00e4va minimal rehabilitering. Bolaget har nu fokus p\u00e5 den fortsatta kliniska utvecklingen och genomf\u00f6r just nu en klinisk fas 2b-studie. Staybles vision \u00e4r att utveckla STA363 som ny standardbehandling f\u00f6r patienter som lider av kronisk diskrelaterad ryggsm\u00e4rta. <\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Bolagets Certified Adviser \u00e4r Svensk Kapitalmarknadsgranskning AB som n\u00e5s p\u00e5 telefonnummer +46 11 32 30 732 eller e-post <\/span><a href=\"mailto:ca@skmg.se\" style=\"text-decoration:none\"><span style=\"color:#0000ff;font-family:arial,helvetica,sans-serif;font-size:9pt\"><u>ca@skmg.se<\/u><\/span><\/a><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\"> <\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Andreas Gerward, VD p\u00e5 Stayble Therapeutics AB, kommer delta p\u00e5 Stora Aktiedagen i G\u00f6teborg den 8 november 2022. \u00c4mnen som kommer ber\u00f6ras inkluderar Staybles marknadspotential, den p\u00e5g\u00e5ende fas IIb-studien och v\u00e4gen fram\u00e5t med p\u00e5g\u00e5ende partnerdiskussioner och de regulatoriska f\u00f6rberedelserna inf\u00f6r fas III-studien.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5611"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5611"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5611\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}